annual cash & cash equivalents:
$174.96M+$47.85M(+37.65%)Summary
- As of today (September 10, 2025), DNLI annual cash & cash equivalents is $174.96 million, with the most recent change of +$47.85 million (+37.65%) on December 31, 2024.
- During the last 3 years, DNLI annual cash & cash equivalents has fallen by -$118.52 million (-40.38%).
- DNLI annual cash & cash equivalents is now -65.50% below its all-time high of $507.14 million, reached on December 31, 2020.
Performance
DNLI Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$898.95M+$81.03M(+9.91%)Summary
- As of today (September 10, 2025), DNLI quarterly cash & cash equivalents is $898.95 million, with the most recent change of +$81.03 million (+9.91%) on June 30, 2025.
- Over the past year, DNLI quarterly cash & cash equivalents has increased by +$2.91 million (+0.32%).
- DNLI quarterly cash & cash equivalents is now -38.83% below its all-time high of $1.47 billion, reached on December 31, 2020.
Performance
DNLI quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
DNLI Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.6% | +0.3% |
| 3 y3 years | -40.4% | -15.9% |
| 5 y5 years | +120.2% | +63.6% |
DNLI Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -40.4% | +37.6% | -32.7% | +9.9% |
| 5 y | 5-year | -65.5% | +120.2% | -38.8% | +63.6% |
| alltime | all time | -65.5% | +469.2% | -38.8% | +404.1% |
DNLI Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $898.95M(+9.9%) |
| Mar 2025 | - | $817.93M(-1.7%) |
| Dec 2024 | $174.96M(+37.6%) | $832.33M(-0.5%) |
| Sep 2024 | - | $836.56M(-6.6%) |
| Jun 2024 | - | $896.04M(-4.4%) |
| Mar 2024 | - | $936.87M(-9.4%) |
| Dec 2023 | $127.11M(-41.7%) | $1.03B(-6.7%) |
| Sep 2023 | - | $1.11B(-6.9%) |
| Jun 2023 | - | $1.19B(-7.6%) |
| Mar 2023 | - | $1.29B(-3.6%) |
| Dec 2022 | $218.04M(-25.7%) | $1.34B(+20.8%) |
| Sep 2022 | - | $1.11B(+3.5%) |
| Jun 2022 | - | $1.07B(+11.6%) |
| Mar 2022 | - | $957.52M(+10.6%) |
| Dec 2021 | $293.48M | $865.41M(-16.7%) |
| Sep 2021 | - | $1.04B(-20.6%) |
| Jun 2021 | - | $1.31B(-7.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2021 | - | $1.41B(-3.8%) |
| Dec 2020 | $507.14M(+538.3%) | $1.47B(+52.9%) |
| Sep 2020 | - | $961.20M(+74.9%) |
| Jun 2020 | - | $549.58M(-6.4%) |
| Mar 2020 | - | $587.25M(+41.4%) |
| Dec 2019 | $79.45M(+3.0%) | $415.36M(-13.4%) |
| Sep 2019 | - | $479.39M(+0.2%) |
| Jun 2019 | - | $478.60M(-1.4%) |
| Mar 2019 | - | $485.48M(+4.6%) |
| Dec 2018 | $77.12M(-64.7%) | $464.30M(+23.8%) |
| Sep 2018 | - | $374.96M(+0.6%) |
| Jun 2018 | - | $372.59M(-0.2%) |
| Mar 2018 | - | $373.40M(-8.1%) |
| Dec 2017 | $218.38M(+448.0%) | $406.23M(+118.6%) |
| Sep 2017 | - | $185.80M(+4.2%) |
| Dec 2016 | $39.85M(+29.6%) | $178.33M |
| Dec 2015 | $30.74M | - |
FAQ
- What is Denali Therapeutics Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Denali Therapeutics Inc.?
- What is Denali Therapeutics Inc. annual cash & cash equivalents year-on-year change?
- What is Denali Therapeutics Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Denali Therapeutics Inc.?
- What is Denali Therapeutics Inc. quarterly cash & cash equivalents year-on-year change?
What is Denali Therapeutics Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of DNLI is $174.96M
What is the all time high annual cash & cash equivalents for Denali Therapeutics Inc.?
Denali Therapeutics Inc. all-time high annual cash & cash equivalents is $507.14M
What is Denali Therapeutics Inc. annual cash & cash equivalents year-on-year change?
Over the past year, DNLI annual cash & cash equivalents has changed by +$47.85M (+37.65%)
What is Denali Therapeutics Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of DNLI is $898.95M
What is the all time high quarterly cash & cash equivalents for Denali Therapeutics Inc.?
Denali Therapeutics Inc. all-time high quarterly cash & cash equivalents is $1.47B
What is Denali Therapeutics Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, DNLI quarterly cash & cash equivalents has changed by +$2.91M (+0.32%)